American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (3997)
  2. Hematologic Malignancies, Division of (3800)
  3. Center for Hematologic Malignancies (3677)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1341)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (986)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (940)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1255)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (3997)
  2. Hematologic Malignancies, Division of (3800)
  3. Center for Hematologic Malignancies (3677)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1341)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (311)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (62)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5172)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5553)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Emergency Medicaid policies enabling equitable access to healthcare coverage for undocumented individuals with hematologic malignancies across the United States
    Meeting Abstract

    Dubey, M.; Santos, P. M. G.; Feldman, K. E.; Narayan, A.; Persaud, S.; Santos, J.; Smith, M.; Anderson, E.; Hong, A.; Yabroff, K. R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Global access to chimeric antigen receptor (CAR) T-cell therapies: Health technology assessment (HTA) of CAR T in G7 countries and Australia
    Meeting Abstract

    Ge, A. Y.; Feldman, W. B.; Kaiser, M. F.; Rejeski, K.; Iacoboni, G.; Dickinson, M. J.; Kesselheim, A. S.; Cliff, E. R. S.
    Blood (2024)

    Fulltext@MSK | Save
  • Disparities in microbiota diversity impacting non-European recipients of 8/8 HLA-matched unrelated donor transplantation
    Meeting Abstract

    Smith, N. G.; Fingrut, W. B.; Waters, N.; Piasevoli, K.; Fei, T.; Slingerland, J.; Peled, J. U.; Ponce, D. M.
    Blood (2024)

    Fulltext@MSK | Save
  • Development of induced pluripotent stem cell-derived t cells exhibiting phenotypic and functional attributes of primary CAR T cells
    Meeting Abstract

    Hancock, B.; Tuncel, J.; Omilusik, K.; O'Connor, A.; Yang, B. H.; Haynes, M.; Yzaguirre, A.; Palomares, K.; Hanok, S. K.; Denholtz, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Cost-effectiveness of eltrombopag plus immunosuppressive therapy versus immunosuppressive therapy alone in adults with severe aplastic anemia in the United States
    Meeting Abstract

    Potnis, K. C.; Ito, S.; Patel, K.; Shallis, R. M.; Podoltsev, N. A.; Kewan, T.; Stempel, J. M.; Mendez, L.; Huntington, S. F.; Stahl, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A healthcare utilization model comparing time toxicity between glofitamab and epcoritamab
    Meeting Abstract

    Torka, P.; Masaquel, A.; Cassoli, L.; Fox, D.; Mangalindan, A.; Major, A.
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 1 study to evaluate the safety and tolerability of a combination autologous CD19 CART cell therapy (SYNCAR-001) and orthogonal IL-2 (STK-009) in subjects with relapsed or refractory CD19 expressing hematologic malignancies (NCT05665062)
    Meeting Abstract

    Palomba, M. L.; Caimi, P. F.; Mei, M.; Hernandez-Ilizaliturri, F.; Shouse, G.; Winter, A. M.; Yedinak, G.; Mou, D.; Huang, N.; Moua, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Obecabtagene autoleucel (obe-cel) for adult relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in the open-label, multi-center, global, single-arm, phase Ib/II FELIX study: The impact of bridging therapies on CAR T-cell expansion and persistence
    Meeting Abstract

    Park, J. H.; Jabbour, E.; Shaughnessy, P.; Logan, A. C.; Sandhu, K. S.; Abedi, M.; Shah, B. D.; Bishop, M. R.; Deangelo, D. J.; Lao-Sirieix, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Isatuximab in relapsed AL amyloidosis: Results of a prospective phase II trial (SWOG S1702)
    Meeting Abstract

    Parker, T. L.; Rosenthal, A.; Sanchorawala, V.; Landau, H.; Campagnaro, E. L.; Kapoor, P.; Neparidze, N.; Girnius, S.; Hagen, P.; Scott, E. C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • First results from the dose escalation part of the phase 1 study of KTX1001, an oral, first-in-class, potent inhibitor of MMSET/NSD2 for relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Bories, P.; Gasparetto, C.; Dingli, D.; Lonial, S.; Usmani, S. Z.; Berdeja, J. G.; Chung, A.; Afrough, A.; Rosiñol, L.; Yee, A. J.; more...
    Blood (2024)

    Fulltext@MSK | Save